Cancer Moonshot℠ - Funding by Research Category
To ensure the Cancer Moonshot goals and approaches were grounded in the best science, NCI convened a Blue Ribbon Panel (BRP) of scientific experts as a working group to the National Cancer Advisory board. In September of 2016, the BRP presented a final report outlining 10 research recommendations that represent areas that are well-positioned to accelerate progress in cancer prevention, diagnosis, treatment and care.
The following research categories align with these 10 recommendations:
| Research Category | Amount1 |
|---|---|
| Network for Direct Patient Engagement | $31,710,990 |
| Cancer Immunotherapy Translational Science Network |
$27,855,827 |
| Therapeutic Target Identification to Overcome Drug Resistance |
$10,851,731 |
| A National Cancer Data Ecosystem for Sharing and Analysis |
$18,807,850 |
| Fusion Oncoproteins in Childhood Cancers |
$2,809,778 |
| Minimize Cancer Treatment’s Debilitating Side Effects |
$7,572,852 |
| Prevention and early detection: Implementation of Evidence-Based Approaches |
$41,412,316 |
| Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care | $0 |
| Generation of Human Tumor Atlases |
$13,152,131 |
| Development of New Enabling Cancer Technologies |
$23,301,652 |
| Total | $177,475,128 |
|
1 Includes new obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, and 2021 carryover accounts. |
|